Consistent with this finding, Velez et al. demonstrated that ACLY inhibition by a combination of bempedoic acid (BA) and palbociclib decreases the viability of MDA-MB-231 breast cancer cells and that ACLY inhibition by BA induces apoptosis in MDA-MB-231 breast cancer cells via elevation of the apoptotic markers cPARP and p-c-Jun [113]. Here, ACLY is linked to breast carcinoma.